Navigate the fast-moving cannabis sector with 420 Investor, a premium service that sends real-time alerts and explanations of the news below and much more.
Summary
- The FDA issued a report about data collection for better understanding CBD safety and quality issues.
- Canadian retail cannabis sales increased 44% in August.
- Health Canada added 4 new licenses, leaving the total now at 784.
- 420 Investor model portfolios have gained 7.1-44.9% year-to-date, while the Global Cannabis Stock Index has lost 4.5%.
Review
The FDA shared a plan on using novel data sources in its effort to better understand safety and quality issues for CBD as it continues to ponder regulations.
August cannabis sales, according to StatsCan, rose 44% to a record C$357 million. Health Canada added 4 licenses, leaving the total at 784, including 12 that are expired, revoked or suspended.
During the week, I shared these insights with subscribers at 420 Investor:
- The Original Cannabis Biotech Company Could Deliver Again
- Cannabis Sub-Sector Review – 10/15/21
- Model Portfolio Composition 10/15/21
Here are some of this week’s highlights for 420 Investor Focus List names:
- CRLBF opened its fifth Pennsylvania dispensary
- CRON launched its first products that contain cannabinoids produced through biosynthesis
- CURLF expanded its B NOBLE brand to six additional states. It also expanded its relationship with Rolling Stone.
- GNLN will be buying DaVinci, a vaporizer company, for up to $20 million in cash, stock and earnouts and milestones. It launched a new line of pre-roll packaging, The Cali by VIBES, with Cookies CEO Berner.
- GRWG invested in Grow Control, which offers an integrated control platform for growers. It also will be developing an accelerator program for social equity and micro license holders.
- TCNNF continued to open Harvest stores and to add to its Florida footprint, which now includes 102 stores. It also added a dispensary in Pittsburgh, giving it 14 in Pennsylvania.
- TLRY hired a former Bacardi GM as President, Tilray Canada, reporting to Jim Meiers, who has been promoted to COO. It named Great North Distributors as its exclusive distributor in all provinces except Quebec.
- UGRO reported that $5.1 million was stolen through fraudulent wire transfers and that it expects to recover the remaining $3 million not yet recovered.
- VLNCF entered the Quebec market. It hired a Charlotte’s Web veteran as VP of Marketing and Business Development for its CBD division, Green Roads.
- VRNOF added $120 million at 8.5% to its credit facility
Market Performance
The Global Cannabis Stock Index posted a new 2021 closing low on Monday before lifting over the balance of the week and then taking it out during trading on Friday. decreasing 2.2% to 42.41:
The index, which lost 34.1% in 2019 and lost 54.9% in 2018 after gaining 91.8% in 2017 and 88.8% in 2016, was up 5.2% in 2020. It has lost 4.5% in 2021 thus far. It currently includes 42 stocks and ended 2020 at 44.39:
Model Portfolios
420 Investor offers three model portfolios for subscribers, including two that are long-term focused and fully invested with a goal of beating the Global Cannabis Stock Index, 420 Opportunity and 420 Quality. 420 Opportunity ended the week valued at $124,147, down 0.3%. The model portfolio, up 17.8% in 2021, gained 35.6% in 2020 and has increased 148.3% since April 2014 despite the large loss in the index since then. 420 Quality ended the week at $172,895, down 0.4% for the week, and is now up 7.1% in 2021 after gaining 42.8% in 2020. The model was launched in March 2017 targeting long-term investors seeking to invest in leading cannabis stocks with low portfolio turnover and has gained 245.8% since inception compared to the 47.4% decline in the index since then. Flying High, which is focused on swing trades, ended the week valued at $365,771, up 1.0%. The model portfolio gained 52.7% in 2020 and is up 44.9% in 2021, and the return since inception in late 2013 has been 3558%.
Outlook
After a strong rally to begin 2019, the cannabis sector experienced a sharp decline over the next year to unprecedented levels due to several negative developments, including the CannTrust fraud, the surprise termination of Bruce Linton as CEO of Canopy Growth, a disappointing roll-out of legalization in Canada, regulatory confusion in the U.S. regarding CBD and a slow roll-out of legalization in California, the vaping crisis and then financial turmoil and market disruptions due to the COVID-19 pandemic. The sector saw capital available to fund expansion dry up, a situation that continues to leave companies operating with negative cash flow severely challenged, as the availability is limited to stronger operators.
Cannabis stocks overreacted and put in a bottom in March 2020, and benefited from a perception that the industry offers strong growth prospects, something that wasn’t clear then. A big change was that the pandemic caused many regulators to permit previously prohibited types of retail activities, like curbside pickup and delivery. The legal market rapidly capitalized on becoming even more convenient than the illicit market, with the ability to order online. States and municipalities moved to broaden adult-use and medical access. Access to capital improved dramatically, and the leading companies began generating large and rapidly growing revenue and profits.
The strong finish to 2020 continued into 2021 after the Democrats took control of the Senate in early January, but the stocks got way ahead of themselves and have been consolidating since then. In addition to concerns that federal legalization will take a longer time than many have expected, there have been some tough comparisons to year-ago sales levels. Additionally, while several institutions embraced the sector early in the year, there has been a lull in additional interest.
There are several potential catalysts ahead, including the FDA (or Congress) providing clarity on CBD regulation, progress in the Canadian legalization that commenced in October 2018 and that is beginning to include a broader set of products and the continued growth in German and Israeli MMJ and other international markets that have been slow to develop. The adult-use implementations in California and Massachusetts for adult-use were slow to roll out but are beginning to show great improvement. Michigan and Illinois legalized for adult-use at the end of 2019, and these markets are showing strong growth that could encourage other states to legalize. Voters in Arizona, Montana, South Dakota and New Jersey all approved adult-use legalization in November, and Connecticut, New Mexico, New York and Virginia have enacted legalization through the legislative process in 2021.
The big themes ahead are likely to be continued cross-industry investment into the sector and more consolidation in Canada and in the U.S., potential federal regulatory reform (SAFE Banking Act and other more comprehensive legislation, which could eliminate 280E taxation and enable trading on higher exchanges for MSOs as well as the broad usage of credit cards for cannabis purchases), steps to enable cannabis research, the roll out of MMJ in Germany, Mexico and in Australia as well as continued advances in South America and potential adult-use legalization in Israel and Mexico, new legal cannabis implementations in AZ, MT, NJ and SD, and MMJ implementations in AL, WV and VA, possible legalization via the legislatures in DE, FL, MD, MN, NH, PA and RI and implementation of the CT, NM, NY and VT commercial programs in 2022 and VA in 2024.
After bottoming in March 2020, the cannabis sector has been in a new bull market. Many companies are generating substantial revenue and some even a profit, and liquidity is much better. The sector has transitioned away from many legacy penny stocks that had never proven that they had viable businesses towards better capitalized companies, many of which have strong management teams and substantial businesses. The investor base has also transitioned, becoming increasingly more institutional.
